Summit X LLC’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,925	Closed	-$12.9K	–	196
2023 Q3	$12.9K	Sell	10,925 -4,000	-27%	-$5.44K	﹤0.01%	180
2023 Q2	$21K	Sell	14,925 -7,000	-32%	-$9.67K	0.01%	269
2023 Q1	$32.9K	Sell	21,925 -8,000	-27%	-$11.2K	0.01%	259
2022 Q4	$47.3K	Buy	29,925 +5,000	+20%	+$6.3K	0.01%	236
2022 Q3	$29K	Sell	24,925 -5,000	-17%	-$7.34K	0.01%	241
2022 Q2	$48K	Sell	29,925 -1,000	-3%	-$1.32K	0.01%	237
2022 Q1	$48K	Sell	30,925 -1,000	-3%	-$1.55K	0.01%	248
2021 Q4	$78K	Buy	31,925 +3,000	+10%	+$7.02K	0.02%	252
2021 Q3	$72K	Sell	28,925 -75	-0.3%	-$192	0.02%	253
2021 Q2	$82K	Sell	29,000 -3,000	-9%	-$7.76K	0.02%	257
2021 Q1	$75K	Buy	32,000 +1,000	+3%	+$2.4K	0.02%	255
2020 Q4	$55K	Buy	31,000 +2,000	+7%	+$2.8K	0.02%	241
2020 Q3	$2	Hold	29,000	–	–	﹤0.01%	439
2020 Q2	$25K	Sell	29,000 -1,700	-6%	-$1.5K	0.01%	202
2020 Q1	$25K	Buy	30,700 +9,500	+45%	+$9.46K	0.01%	185
2019 Q4	$19K	Buy	21,200 +3,000	+16%	+$2.5K	0.01%	229
2019 Q3	$18K	Hold	18,200	–	–	0.01%	226
2019 Q2	$21K	Sell	18,200 -300	-2%	-$346	0.01%	230
2019 Q1	$25K	Sell	18,500 -1,500	-8%	-$1.87K	0.01%	232
2018 Q4	$19K	Buy	20,000 +569	+3%	+$872	0.01%	200
2018 Q3	$40K	Buy	19,431 +5,715	+42%	+$12K	0.02%	219
2018 Q2	$24K	Buy	13,716 +571	+4%	+$1.15K	0.01%	205
2018 Q1	$30K	Buy	+13,145	New	+$30.8K	0.02%	180
2017 Q3	–	Sell	-14,630	Closed	-$41K	–	188
2017 Q2	$41K	Buy	+14,630	New	+$40.9K	0.03%	178

Other funds holding LCTX